EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan’s 8th Annual Genetic Medicines Conference:
- Fireside chat on Monday, September 30, 2024, 2:30 PM – 3:00 PM ET with Brian Thomas, CEO and Founder, Dr. Sarah Noonberg, CMO, and Alan Brooks, SVP Preclinical.
- Panel discussion titled, Genome editing for gene insertion and gene correction – where we are and what’s next, on Monday, September 30, 2024, 5:00 PM – 5:30 PM ET with Brian C. Thomas, CEO and Founder.
A live conference webcast of the fireside chat will be available in the investor section of the company’s website at https://ir.metagenomi.co/. Replays for both events will be available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://‹metageno‹mi‹.co.
Cautionary Note Regarding Forward‹Looking Statements
This press release contains ‹forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ‹anticipate, ‹believe, ‹could, ‹estimate, ‹expect, ‹goal, ‹intend, ‹look forward to, ‹may, ‹plan, ‹potential, ‹predict, ‹project, ‹should, ‹will, ‹would and similar expressions,…
Click Here to Read the Full Original Article at All News…
